A randomized, observer‐blind, vehicle‐control, multi‐center clinical investigation for assessing the efficacy and tolerability of a 1% ectoine and hyaluronic acid 0.1%‐containing medical device in pediatric patients with mild‐to‐moderate atopic dermatitis

Alexopoulos, A.; Dakoutrou, Maria; Nasi, Lamprini; Thanopoulou, I; Kakourou, Talia; Kontara, Louiza; Douladiris, Nikolaos; Galani, Maria; Xepapadaki, Paraskevi; Doxani, Chrysoula; Mprotsis, Theodoros; Ζιντζαράς, Ηλίας; Papadopoulos, Nikolaos G.; Kanaka-Gantenbein, Christina; Chrousos, George P.

doi:10.1111/pde.15117

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides these application areas, ectoine has been shown to be used in relieving mucositis, treating atopic dermatitis, reducing the effect of irradiation and ameliorating the Duchenne Muscular Dystrophy's symptoms (Fondevilla et al 2022;Merckx et al 2022;Alexopoulos et al 2023). This compound has also been demonstrated to be useful in enhancing some industrial processes including the growth of an industrial lactic acid producer bacterium (Tetragenococcus halophila) and an ethanol producer bacterium (Zymomonas mobilis) (Baliarda et al 2003;Zhang et al 2008).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Valorisation of cheese whey for ectoine production by Halomonas neptunia

Orhan,

Ceyran

2023

Int J of Dairy Tech

View full text Add to dashboard Cite

The production of ectoine, a valuable compound with significant potential as an osmoprotectant, antioxidant, macromolecule protector and anti‐inflammatory agent, was achieved by a lactose‐utilising bacterial strain. We explore the feasibility of using cheese whey, a waste product rich in lactose and amino acids, as a growth medium. The optimisation of various parameters was conducted to maximise ectoine yield. The highest ectoine production was achieved using 50% diluted whey, pH 6.50, 10% NaCl, 150 rpm and 30°C. This is the first study in which whey was efficiently utilised to produce ectoine by Halomonas neptunia.

show abstract

Section: Introductionmentioning

confidence: 99%

“…2022; Alexopoulos et al . 2023). This compound has also been demonstrated to be useful in enhancing some industrial processes including the growth of an industrial lactic acid producer bacterium ( Tetragenococcus halophila ) and an ethanol producer bacterium ( Zymomonas mobilis ) (Baliarda et al .…”

Section: Introductionmentioning

confidence: 99%

Valorisation of cheese whey for ectoine production by Halomonas neptunia

Orhan,

Ceyran

2023

Int J of Dairy Tech

View full text Add to dashboard Cite

show abstract

Topical anti-inflammatory treatments for eczema: network meta-analysis

Lax,

Van Vogt,

Candy

et al. 2024

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Eczema (atopic dermatitis) is the most burdensome skin condition worldwide and cannot currently be prevented or cured. Topical anti‐inflammatory treatments are used to control eczema symptoms, but there is uncertainty about the relative effectiveness and safety of different topical anti‐inflammatory treatments. Objectives To compare and rank the efficacy and safety of topical anti‐inflammatory treatments for people with eczema using a network meta‐analysis. Search methods We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries on 29 June 2023, and checked the reference lists of included studies. Selection criteria We included within‐participant or between‐participant randomised controlled trials (RCTs) in people of any age with eczema of any severity, but excluded trials in clinically infected eczema, seborrhoeic eczema, contact eczema, or hand eczema. We included topical anti‐inflammatory treatments used for at least one week, compared with another anti‐inflammatory treatment, no treatment, or vehicle/placebo. Vehicle is a 'carrier system' for an active pharmaceutical substance, which may also be used on its own as an emollient for dry skin. We excluded trials of topical antibiotics used alone, complementary therapies, emollients used alone, phototherapy, wet wraps, and systemic treatments. Data collection and analysis We used standard Cochrane methods. Primary outcomes were patient‐reported eczema symptoms, clinician‐reported eczema signs and investigator global assessment. Secondary outcomes were health‐related quality of life, long‐term control of eczema, withdrawal from treatment/study, and local adverse effects (application‐site reactions, pigmentation changes and skin thinning/atrophy were identified as important concerns through patient and public involvement). We used CINeMA to quantify our confidence in the evidence for each outcome. Main results We included 291 studies involving 45,846 participants with the full spectrum of eczema severity, mainly conducted in high‐income countries in secondary care settings. Most studies included adults, with only 31 studies limited to children aged < 12 years. Studies usually included male and female participants, multiple ethnic groups but predominantly white populations. Most studies were industry‐funded (68%) or did not report their funding sources/details. Treatment duration and trial participation were a median of 21 and 28 days (ranging from 7 days to 5 years), respectively. Interventions used were topical corticosteroids (TCS) (172), topical calcineurin inhibitors (TCI) (134), phosphodiesterase‐4 (PDE‐4) inhibitors (55), janus kinase (JAK) inhibitors (30), aryl hydrocarbon receptor activators (10), or other topical agents (21). Comparators included vehicle (170) or other anti‐inflammatory treatments. The risk of bias was high in 2...

show abstract